Peroxisome Proliferator-Activated Receptor-γ in Lung Cancer: Defining Specific Versus “Off-Target― Effectors
- 1 November 2007
- journal article
- review article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 2 (11), 989-992
- https://doi.org/10.1097/jto.0b013e318158cf0a
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information SystemBMC Medicine, 2007
- PPARγ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cellsCancer Biology & Therapy, 2007
- Cancer risks in thiazolidinedione users compared to other anti‐diabetic agentsPharmacoepidemiology and Drug Safety, 2006
- Apoptosis induced by troglitazone is both peroxisome proliferator‐activated receptor‐γ‐ and ERK‐dependent in human non‐small lung cancer cellsJournal of Cellular Physiology, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Kinase signaling cascades that modulate peroxisome proliferator-activated receptorsCurrent Opinion in Cell Biology, 2005
- Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC)Oncogene, 2004
- Troglitazone, a Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Selectively Induces the Early Growth Response-1 Gene Independently of PPARγJournal of Biological Chemistry, 2003
- Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancerLung Cancer, 2002
- The Mechanisms of Action of PPARsAnnual Review of Medicine, 2002